The traditional approach to cancer is that the patient must view cancer as the enemy and engage in a war to vanquish that enemy. Ann Wax, RN, argues that this approach is incorrect and invariably leads to pain, self doubt, and depression. Instead, she argues that one must find calm and inner-peace first, in order to promote healing.

Despite success with treatment when diagnosed early, breast cancer is still one of the most fatal forms of cancer for women. Imaging diagnosis is still one of the most efficient ways to detect early breast changes with mammography among the most used techniques. However, there are other techniques that have emerged as alternatives or even complementary tests in the early detection of breast lesions (e.g., breast thermography and electrical impedance tomography). Artificial intelligence can be used to optimize image diagnosis, increasing the reliability of the reports and supporting professionals who do not have enough knowledge or experience to make good diagnoses. Biomedical Computing for Breast Cancer Detection and Diagnosis is a collection of research that presents a review of the physiology and anatomy of the breast; the dynamics of breast cancer; principles of pattern recognition, artificial neural networks, and computer graphics; and the breast imaging techniques and computational methods to support and optimize the diagnosis. While highlighting topics including mammograms, thermographic imaging, and intelligent systems, this book is ideally designed for medical oncologists, surgeons, biomedical engineers, medical imaging professionals, cancer researchers, academicians, and students in medicine, biomedicine, biomedical engineering, and computer science.

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers.

Currently, intensive effort is being directed toward the identification of molecular targets that can provide approaches to the development of novel therapeutic strategies in cancer management. This book focuses on metastasis-associated genes, metastasis promoter and suppressor genes, which relate specifically to behavioral alterations of cancer cells in epithelial mesenchymal transition, cancer stem cell maintenance and propagation, and to the acquisition of invasive and metastasis faculty. The function of these genes has implications for cell cycle regulation and cell proliferation and so constitute an essential element in cancer growth and dissemination. The emphasis in this book is on how appropriate these genes are as molecular targets and how practicable are the constituents of their signal transduction systems as potential candidates and how accessible they are to targeted therapy. Written in a straightforward and clear style with background information supporting the new research, this book will be useful for students and researchers in cancer therapies.
Identifies molecular targets and their accessibility for therapeutic interventionProvides information on biological features of tumor development and dissemination Background information provided for each topic

In this issue of Radiologic Clinics, guest editor Dr. Hillary W. Garner brings her considerable expertise to the topic of Imaging of Bone and Soft Tissue Tumors and Mimickers. Top experts provide timely articles on the imaging findings and other relevant clinical information of frequently encountered benign and malignant tumors of bone and soft tissue, in addition to separate reviews on common and potentially confusing tumor mimics. In addition, orthopaedic oncologists have contributed valuable perspectives on how they incorporate imaging information into their patient care plans. Contains 11 relevant, practice-oriented topics including bone tumors: what the oncology team wants to know; bone tumors: imaging features of common and rare benign entities; bone tumors: common mimickers; soft tissue tumors: what the oncology team wants to know; soft tissue tumors: common mimickers; bone and soft tissue tumors: horizons in radiomics and artificial intelligence; and more. Provides in-depth clinical reviews on imaging of bone and soft tissue tumors and mimickers, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Proton beam therapy is an emerging technology with promise of revolutionizing the treatment of cancer. While nearly half of all patients diagnosed with cancer in the US receive radiation therapy, the majority is delivered via electron accelerators, where photons are used to irradiate cancerous tissue. Because of the physical properties of photon beams, photons may deposit energy along their entire path length through the body. On the other hand, a protonbeamdirected ata tumor travels in a straight trajectory towards its target, gives off most of its energy at a defined depth called the Bragg peak, and then stops. While photons often deposit more energy within the healthy tissues of the body than within the cancer itself, protons can deposit most of their cancer-killing energy within the area of the tumor. As a result, in the properly selected patients, proton beam therapy has the ability to improve cure rates by increasing the dose delivered to the tumor and simultaneously reduce side-effects by decreasing the dose to surrounding tissue. The benefits of proton beam therapy in delivering a lethal hit to the target while sparing surrounding normal tissues from radiation are becoming applicable to an increasing number of patients and a growing list of conditions. In this book, the author will guide the reader through existing evidence supporting proton beam therapy for pediatric cancer, prostate cancer, lung cancer, brain tumors, spinal tumors, and several other conditions. The book will discuss which conditions are suitable for treatment with proton beam therapy, how the treatment is delivered, and the current data supporting its use."

th America th America

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored. This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers.

Multidrug-resistant bacteria play a significant role in public health by destroying the potency of existing antibiotics. Meanwhile, cancer remains one of the most common health problems that impact society, resulting in many deaths worldwide. Novel strategies are required to combat antimicrobial resistance and create efficient anticancer drugs that could revolutionize treatment. Nanomedicine is one such innovation that plays a significant role in developing alternative and more effective treatment strategies for antimicrobial resistance and cancer theranostics. The Handbook of Research on Nano-Strategies for Combatting Antimicrobial Resistance and Cancer is an essential scholarly resource that examines (1) how to overcome the existing, traditional approaches to combat antimicrobial resistance and cancer; (2) how to apply multiple mechanisms to target the cancer cells and microbes; and (3) how the nanomaterials can be used as carriers. Featuring a range of topics such as bacteriophage, nanomedicine, and oncology, this book is ideal for molecular biologists, microbiologists, nanotechnologists, academicians, chemists, pharmacists, oncologists, researchers, healthcare professionals, and students.

This issue of PET Clinics focuses on Total Body PET Imaging, and is edited by Drs. Lorenzo Nardo, Ramsey Badawi, Joel S. Karp and Austin Pantel. Articles will include: UC Davis update on the uEXPLORER; Zhongshan update on the uEXPLORER; UPenn update on the PennPET Explorer; Total body imaging instrumentation design considerations; 3D/4D reconstruction and quantitative total body imaging; Analysis of 4D data for total body imaging; Total body imaging and cancer; Total body imaging and metabolic disease; Total body imaging and infection; Total body imaging and musculoskeletal disease; Total body imaging and cardiovascular disease; Total body imaging and cardiac applications; Total body imaging and neuroimaging; and more!

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma: Translational and Clinical Outcomes, Volume Three provides comprehensive information about ongoing research and clinical data on liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. This updated volume discusses topics such as clinical and safety assessment of HCC patients, liver transplantation as a therapeutic option, immunotherapy interventions, and image-based surveillance. In addition, it discusses immunohistology of HCC-enabled precision medicine and artificial intelligence for hepatocellular carcinomas. This is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.